NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free EOLS Stock Alerts $13.59 -0.11 (-0.80%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$13.30▼$13.8250-Day Range$11.43▼$14.0952-Week Range$7.07▼$15.43Volume712,134 shsAverage Volume689,010 shsMarket Capitalization$850.73 millionP/E RatioN/ADividend YieldN/APrice Target$20.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Evolus alerts: Email Address Evolus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside51.6% Upside$20.60 Price TargetShort InterestBearish9.69% of Float Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.47Based on 12 Articles This WeekInsider TradingSelling Shares$955,560 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.61) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector252nd out of 921 stocksPharmaceutical Preparations Industry104th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 2 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.69% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Evolus has recently increased by 3.02%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEvolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.Environmental SustainabilityThe Environmental Impact score for Evolus is -1.27. Previous Next 1.9 News and Social Media Coverage News SentimentEvolus has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Evolus this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $955,560.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.61) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -12.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -12.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 46.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Evolus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”Man who spotted Apple at $1.49 says: "Buy These 6 AI Stocks."And these will be the biggest winners About Evolus Stock (NASDAQ:EOLS)Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More EOLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EOLS Stock News HeadlinesMay 16 at 1:40 PM | insidertrades.comDavid N. Gill Sells 3,643 Shares of Evolus, Inc. (NASDAQ:EOLS) StockMay 15, 2024 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 2,423 SharesMay 16 at 8:22 AM | finance.yahoo.comDirector Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)May 16 at 8:22 AM | finance.yahoo.comDirector David Gill Sells 10,361 Shares of Evolus Inc (EOLS)May 16 at 7:08 AM | americanbankingnews.comDavid Moatazedi Sells 16,051 Shares of Evolus, Inc. (NASDAQ:EOLS) StockMay 15, 2024 | finance.yahoo.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO SummitMay 15, 2024 | businesswire.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO SummitMay 13, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Evolus (EOLS)May 12, 2024 | americanbankingnews.comEvolus' (EOLS) Buy Rating Reiterated at Needham & Company LLCMay 10, 2024 | finance.yahoo.comEvolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the YearMay 10, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | businesswire.comEvolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the YearMay 10, 2024 | markets.businessinsider.comEvolus’s Strong Q1 Performance and Solid Growth Trajectory Justify Buy RatingMay 10, 2024 | markets.businessinsider.comEvolus Outperforms Expectations with Strong Q1 Sales and Promising Growth TrajectoryMay 10, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Evolus (NASDAQ:EOLS)May 9, 2024 | finance.yahoo.comEvolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comEvolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ...May 7, 2024 | investorplace.comEOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comEvolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant GrowthMay 7, 2024 | businesswire.comEvolus Reports First Quarter 2024 Results and Provides Business UpdateMay 3, 2024 | finance.yahoo.comThe 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%April 23, 2024 | businesswire.comEvolus to Report First Quarter Financial Results on May 7, 2024April 18, 2024 | investing.comEvolus reports 6-month efficacy of Jeuveau in glabellar lines studyApril 17, 2024 | finance.yahoo.comEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®See More Headlines Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/18/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees273Year FoundedN/APrice Target and Rating Average Stock Price Target$20.60 High Stock Price Target$27.00 Low Stock Price Target$16.00 Potential Upside/Downside+51.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,690,000.00 Net Margins-27.31% Pretax Margin-27.22% Return on EquityN/A Return on Assets-28.50% Debt Debt-to-Equity Ratio6.54 Current Ratio3.21 Quick Ratio2.96 Sales & Book Value Annual Sales$202.09 million Price / Sales4.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book46.86Miscellaneous Outstanding Shares62,600,000Free Float59,220,000Market Cap$850.73 million OptionableOptionable Beta1.47 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. David Moatazedi (Age 46)President, CEO & Director Comp: $1.27MMs. Sandra Beaver (Age 46)Chief Financial Officer Comp: $372.23kDr. Rui Avelar C.CFP (Age 62)Dip.SportMed, M.D., Chief Medical Officer and Head of Research & Development Comp: $682.03kMr. Nareg SagherianHead of Global Investor Relations & Corporate CommunicationsMr. Jeffrey J. PlumerGeneral CounselMr. Kurt KnabVice President of SalesMs. Tomoko Yamagishi-DresslerChief Marketing OfficerMs. Jessica NovakSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsArcturus TherapeuticsNASDAQ:ARCTLongboard PharmaceuticalsNASDAQ:LBPHALX OncologyNASDAQ:ALXOTango TherapeuticsNASDAQ:TNGXDisc MedicineNASDAQ:IRONView All CompetitorsInsiders & InstitutionsZimmer Partners LPBought 300,000 shares on 5/17/2024Ownership: 0.479%FourWorld Capital Management LLCSold 50,000 shares on 5/16/2024Ownership: 0.245%California State Teachers Retirement SystemBought 739 shares on 5/16/2024Ownership: 0.077%Price T Rowe Associates Inc. MDBought 1,637 shares on 5/15/2024Ownership: 0.064%PEAK6 Investments LLCBought 800 shares on 5/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EOLS Stock Analysis - Frequently Asked Questions Should I buy or sell Evolus stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EOLS shares. View EOLS analyst ratings or view top-rated stocks. What is Evolus' stock price target for 2024? 3 equities research analysts have issued 1-year target prices for Evolus' stock. Their EOLS share price targets range from $16.00 to $27.00. On average, they expect the company's share price to reach $20.60 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price. View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts. How have EOLS shares performed in 2024? Evolus' stock was trading at $10.53 at the beginning of 2024. Since then, EOLS shares have increased by 29.1% and is now trading at $13.59. View the best growth stocks for 2024 here. When is Evolus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our EOLS earnings forecast. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.05. The firm had revenue of $61 million for the quarter, compared to analyst estimates of $61.14 million. What ETFs hold Evolus' stock? ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Evolus issued on next quarter's earnings? Evolus updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $262.8 million. What is David Moatazedi's approval rating as Evolus' CEO? 1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO). When did Evolus IPO? Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.64%), Rice Hall James & Associates LLC (1.52%), Lord Abbett & CO. LLC (1.33%), BNP Paribas Financial Markets (0.65%), Zimmer Partners LP (0.48%) and Essex Investment Management Co. LLC (0.41%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Karah Herdman Parschauer, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EOLS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.